Drug Trial Radar · NCT05721729
Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
15
Actual
Start
Jun 23, 2023
Primary completion
May 1, 2024
Study completion Jun 1, 2025
Sponsor
- Lead sponsor
- Vogenx, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 10, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2 crossover, randomized, placebo-controlled, single-blind, repeat dose study in PBH subjects to determine the effect of mizagliflozin on adverse events and postprandial glucose excursions.
Conditions
- Postbariatric Hypoglycemia
Interventions
MizagliflozinDrug
Encapsulated
PlaceboDrug
Encapsulated
Primary outcomes
What the sponsor says the trial is designed to measure.
- Glucose NadirTime frame: 0-3 hours following MMTT
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Stanford
Palo Alto, California
University of Colorado / Anschutz Medical Campus
Aurora, Colorado
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.